ReviewFrontiers in oncology2025
The pathogenesis of benign prostatic hyperplasia and the roles of Prdx3, oxidative stress, pyroptosis and autophagy:a review.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The gut-liver/bile axis: Gut microbiota and bacterial extracellular vesicles remodeling hepatobiliary pathogenesis.iScience · 2026Review
- Systemic Oxidative and Nitrosative Stress in Benign Prostatic Hyperplasia.Antioxidants (Basel, Switzerland) · 2026Article
- Uroprotective effect of diarylpropionitrile versus finasteride on rat model of testosterone-induced prostatic hyperplasia.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benign prostatic hyperplasia (BPH) is driven by hormonal and inflammatory mechanisms, yet emerging factors such as peroxiredoxin 3 (Prdx3), oxidative stress (OS), pyroptosis, and autophagy remain understudied. This review synthesizes their roles in BPH pathogenesis. We demonstrate that Prdx3 inhibits autophagy, exacerbates OS, and induces pyroptosis, ultimately promoting prostate cell proliferation. Paradoxically, while Prdx3 mitigates OS, its interaction with autophagy amplifies oxidative damage. These findings challenge conventional antioxidant therapies, suggesting that enhancing antioxidant capacity may inadvertently worsen BPH progression. Our analysis provides novel insights into therapeutic strategies targeting these pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.